ETF Managers Group’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

ETF Managers Group’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$46.6K	Buy	18,339 +4,490	+32%	+$8.87K	﹤0.01%	662
2022 Q4	$25.9K	Sell	13,849 -2,341	-14%	-$5.84K	﹤0.01%	506
2022 Q3	$42K	Sell	16,190 -1,022	-6%	-$2.54K	﹤0.01%	673
2022 Q2	$35K	Buy	17,212 +1,988	+13%	+$4.34K	﹤0.01%	723
2022 Q1	$45K	Buy	15,224 +51	+0.3%	+$192	﹤0.01%	661
2021 Q4	$68K	Sell	15,173 -2,000	-12%	-$9.49K	﹤0.01%	654
2021 Q3	$85K	Buy	17,173 +3,329	+24%	+$18.3K	﹤0.01%	644
2021 Q2	$94K	Sell	13,844 -137	-1%	-$1.11K	﹤0.01%	623
2021 Q1	$96K	Sell	13,981 -8,218	-37%	-$59.2K	﹤0.01%	640
2020 Q4	$138K	Sell	22,199 -3,235	-13%	-$19K	﹤0.01%	589
2020 Q3	$140K	Buy	25,434 +12,864	+102%	+$63.7K	﹤0.01%	593
2020 Q2	$64K	Buy	+12,570	New	+$55.8K	﹤0.01%	589

Other funds holding PRTK

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

NAM

Nexpoint Asset Management Dallas, Texas $1.5B AUM 83.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

GAI

General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Bruce & Co Chicago, Illinois $369M AUM 50.95% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return

ETF Managers Group's PRTK Position: Q1 2023 in Review

ETF Managers Group increased its Paratek Pharmaceuticals, Inc. (PRTK) stake by 32% in Q1 2023, buying an estimated $8.87K and bringing the position to 18,339 shares worth $46.6K. The position accounts for ﹤0.01% of the portfolio, ranked #662.

ETF Managers Group first reported a position in PRTK in Q2 2020 and has held it in 12 quarters since. The position peaked at $140K in Q3 2020. 63 funds tracked by Wall St. Rank hold PRTK as of Q1 2023.

ETF Managers Group held 18,339 shares of Paratek Pharmaceuticals, Inc. worth $46.6K as of Q1 2023.
ETF Managers Group bought 4,490 Paratek Pharmaceuticals, Inc. shares in Q1 2023, an estimated $8.87K.
Paratek Pharmaceuticals, Inc. made up ﹤0.01% of ETF Managers Group's portfolio in Q1 2023, its #662 holding.
ETF Managers Group first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2020 and has held it in 12 quarters since.
ETF Managers Group's Paratek Pharmaceuticals, Inc. position peaked at $140K in Q3 2020.
63 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2023.

Based on ETF Managers Group's 13F filing for Q1 2023, filed 18 Apr 2023.